Why the study?
Do new oral anticoagulants improve effectiveness compared to vitamin K antagonists in patients with atrial fibrillation?
Do new oral anticoagulants improve effectiveness compared to vitamin K antagonists in patients with atrial fibrillation?
This review discusses the potential of new oral anticoagulants to be more effective than vitamin K antagonists in reducing thromboembolic risk in patients with atrial fibrillation.
May support NOAC preference over VKAs in AF; leaves open need for confirmatory RCTs before practice change.
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its prevalence is known to increase with age and with an aging population AF is likely to become even more common. Although sometimes patients with AF remain asymptomatic, it is now recognized that AF is far from “benign” conferring a significant risk increase in morbidity and mortality. Restoration of sinus rhythm and rate-limiting medication help with symptoms; however, anticoagulation remains essential in reducing thromboembolic risk. The uptake of appropriate anticoagulation with vitamin K antagonists has increased significantly in the last few decades and this review will analyze whether the new oral anticoagulants might prove to be even more effective than existing vitamin K antagonists.
No takes yet. Share an insight, caveat, or question.
Mallouppas et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: